May 17, 2018
Zymeworks Daiichi I-O deal could potentially be worth USD 485 million Zymeworks and Daiichi Sankyo teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the curtains. The pair is now entering into a new license agreement with a potential deal worth of around USD 484.7 million....
Read More...
May 16, 2018
A group of Researchers at Imperial College London created a molecule that can successfully block multiple strains of the common cold by targeting a protein required for the survival of the virus. The newly created molecule (IMP-1088) resides inside a protein in cells called N-myristoyltransferase (NMT). After invadi...
Read More...
May 11, 2018
Hematopoietic stem cells (HSCs) are characterized by the ability to self-renew and differentiate into all mature blood lineages. Stromal interactions with soluble and cell-bound cytokines structures the differentiations and proliferation of hematopoietic cells. Hematopoietic stem cell transplantation (HSCT) is the i...
Read More...
May 09, 2018
Japan's largest drugmaker Takeda has successfully closed a deal worth USD 62 billion to buy another pharma giant Shire grabbing a place in the top 10 pharmaceutical company list. This is the biggest pharma acquisition of this year so far. Takeda was trying to close a deal for quiet a long time and the news came on t...
Read More...
Apr 24, 2018
FDA still not completely satisfied with Kamada’s inhaled AAT drug(Synthetic Biologics) Kamada is stuck again with a new obstacle in its way to bring the first inhaled treatment for alpha-1 antitrypsin (AAT) deficiency in the market as an alternative to currently present intravenous drugs. The company specializes in ...
Read More...
Apr 18, 2018
Positive Phase 1 data supports Cyclacel’s plans for CDK2/9 inhibitor CYC065 Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares. After that the attention was shifted towards an early-stage CDK inhibitor. As per the latest results presented by the company CD...
Read More...
Apr 16, 2018
Signal Transducer and Activator of Transcription (STAT ) is a family of cytoplasmic transcription factors comprising of 7 members-STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. The STAT factors are activated by tyrosine kinase which could be either receptor associated as Janus Kinase (JAKs) or intrinsic tyro...
Read More...
Apr 13, 2018
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder which is described as the inflammation of nerve roots and peripheral nerves and destruction of the fatty protective covering (myelin sheath) over the nerves. The disease is a chronic form of acute inflammatory demyelinating poly...
Read More...
Apr 12, 2018
Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering. Out of total funding amount around USD 100 million will be used to build commerc...
Read More...
Apr 10, 2018
Hepatic encephalopathy (HE) can be described as deterioration of brain function occurring due to accumulation of toxic substances in the blood which ultimately reach the brain. People with long-standing or chronic liver disorder are at high risk. The disease may also be triggered by bleeding in the digestive tract,...
Read More...
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
Newsletter/Whitepaper